Candice Hammerton, NP
Family · Lewiston, MENPI 1558306910
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,580 of the $4,186 with a category attached, or 85.5%. It is spread thinly across 35 manufacturers, the largest accounting for just 12.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,344, 3.4 times the $391 reported in 2021. Among family clinicians in ME with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 159 payments — averaging $26.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$529
- Johnson & Johnson$472
- Sumitomo Pharma America, Inc.$437
- AstraZeneca$355
- AbbVie$248
- Bayer$224
- plus $2K from 29 others
What the payments were for
- Food & beverage$3,58086%
- Education$60614%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 16 | $529 |
| Johnson & Johnson | 10 | $472 |
| Sumitomo Pharma America, Inc. | 23 | $437 |
| AstraZeneca | 14 | $355 |
| AbbVie(2 entities) | 9 | $248 |
| Bayer | 10 | $224 |
| Merck | 8 | $183 |
| Urogen Pharma, Inc. | 5 | $182 |
| Tolmar, Inc. | 7 | $160 |
| Ferring Pharmaceuticals Inc. | 9 | $159 |
| Tolmar Pharmaceuticals, Inc. | 2 | $107 |
| Olympus America Inc. | 5 | $106 |
| 180 Medical, Inc. | 4 | $103 |
| Teleflex LLC | 3 | $92 |
| Pfizer | 4 | $83 |
| Coloplast | 4 | $78 |
| Progenics Pharmaceuticals, Inc. | 3 | $78 |
| Procept Biorobotics Corporation | 1 | $65 |
| Myriad Genetic Laboratories, Inc. | 3 | $63 |
| Intuitive Surgical | 1 | $63 |
| Dentsply IH AB | 1 | $53 |
| Amgen | 2 | $46 |
| Convatec Inc. | 1 | $40 |
| Axonics, Inc. | 2 | $36 |
| Myovant Sciences Inc. | 2 | $36 |
| Halozyme Inc | 1 | $28 |
| Boston Scientific | 1 | $21 |
| Urovant Sciences Inc | 1 | $21 |
| Dentsply IH Inc. | 1 | $20 |
| Sanofi | 1 | $20 |
| Foundation Medicine, Inc. | 1 | $19 |
| Antares Pharma, Inc. | 1 | $18 |
| Rochester Medical Corporation | 1 | $15 |
| Novartis | 1 | $14 |
| Calyxo, Inc. | 1 | $13 |
How this compares
$4,186 in reported general payments places this provider in the 95th percentile of 545 family providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 206 | $194,286 |
| GemtesaVibegron | 49 | $52,211 |
| Solifenacin Succinate | 162 | $13,708 |
| Tamsulosin Hcl | 583 | $10,944 |
| Trimethoprim | 71 | $10,640 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 85 | $9,073 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 299 | $6,873 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 147 | $6,006 |
| Oxybutynin Chloride ErOxybutynin Chloride | 91 | $4,722 |
| ToviazFesoterodine Fumarate | 14 | $3,733 |
| Finasteride | 278 | $3,588 |
| Potassium Citrate ErPotassium Citrate | 27 | $2,774 |
| Methenamine Hippurate | 30 | $2,328 |
| Tolterodine Tartrate ErTolterodine Tartrate | 25 | $1,805 |
| NitrofurantoinNitrofurantoin Macrocrystal | 25 | $1,569 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $529 | $194,286206 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $437 | $52,21149 claims |
| PfizerToviaz | $83 | $3,73314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 545 family providers in Maine.
Other family in Lewiston
- Natalie BubierLewiston$5K
- Lauren BlaisLewiston$3K
- Sheila HospidalesLewiston$2K
- Samantha HeweyLewiston$2K
- Mia RapollaFalmouth$193K
- Patti DupreyKennebunk$35K
- Amanda WilliamsPortland$8K
- Jamie PiacentiniScarborough$6K
- Rosemary PainePortland$6K
- Brea SwihartAugusta$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.